Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.

Details

Ressource 1Download: BIB_1AD370581931.P001.pdf (462.44 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_1AD370581931
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.
Journal
Cns Drugs
Author(s)
Du Pasquier R.A., Pinschewer D.D., Merkler D.
ISSN
1172-7047 (Print)
ISSN-L
1172-7047
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
28
Number
6
Pages
535-558
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Abstract
Multiple sclerosis (MS) is a life-long, potentially debilitating disease of the central nervous system (CNS). MS is considered to be an immune-mediated disease, and the presence of autoreactive peripheral lymphocytes in CNS compartments is believed to be critical in the process of demyelination and tissue damage in MS. Although MS is not currently a curable disease, several disease-modifying therapies (DMTs) are now available, or are in development. These DMTs are all thought to primarily suppress autoimmune activity within the CNS. Each therapy has its own mechanism of action (MoA) and, as a consequence, each has a different efficacy and safety profile. Neurologists can now select therapies on a more individual, patient-tailored basis, with the aim of maximizing potential for long-term efficacy without interruptions in treatment. The MoA and clinical profile of MS therapies are important considerations when making that choice or when switching therapies due to suboptimal disease response. This article therefore reviews the known and putative immunological MoAs alongside a summary of the clinical profile of therapies approved for relapsing forms of MS, and those in late-stage development, based on published data from pivotal randomized, controlled trials.
Pubmed
Web of science
Open Access
Yes
Create date
11/12/2014 18:33
Last modification date
20/08/2019 12:51
Usage data